Suppr超能文献

重度多种羧化酶缺乏症患者全羧化酶合成酶的半衰期缩短。

Reduced half-life of holocarboxylase synthetase from patients with severe multiple carboxylase deficiency.

作者信息

Bailey Lisa M, Ivanov Ruby A, Jitrapakdee Sarawut, Wilson Callum J, Wallace John C, Polyak Steven W

机构信息

School of Molecular and Biomedical Science, The University of Adelaide, Adelaide, South Australia 5005, Australia.

出版信息

Hum Mutat. 2008 Jun;29(6):E47-57. doi: 10.1002/humu.20766.

Abstract

Multiple carboxylase deficiency is a clinical condition caused by defects in the enzymes involved in biotin metabolism, holocarboxylase synthetase (HLCS) or biotinidase. HLCS deficiency is a potentially fatal condition if left untreated, although the majority of patients respond to oral supplementation of 10-20 mg/day of biotin. Patients who display incomplete responsiveness to this therapy have a poor long-term prognosis. Here we investigated cell lines from two such HLCS-deficient patients homozygous for the c.647T>G p.L216R allele. Growth of the patients' fibroblasts was compromised compared with normal fibroblasts. Also the patient cells were not sensitive to biotin-depletion from the media, and growth rates could not be restored by re-administration of biotin. The molecular basis for the HLCS deficiency was further investigated by characterisation of the p.L216R protein. The HLCS mRNA was detected in MCD and normal cell lines. However, protein and enzyme activity could not be detected in the patients' cells. In vitro kinetic analysis revealed that enzyme activity was severely compromised for recombinantly expressed p.L216R and could not be increased by additional biotin. Furthermore, the turn-over rate for the mutant protein was double that of wildtype HLCS. These results help provide a molecular explanation for the incomplete biotin-responsiveness of this p.L216R form of HLCS.

摘要

多种羧化酶缺乏症是一种由生物素代谢相关酶(全羧化酶合成酶(HLCS)或生物素酶)缺陷引起的临床病症。HLCS缺乏症若不治疗可能会致命,不过大多数患者对每日口服10 - 20毫克生物素的补充有反应。对这种治疗反应不完全的患者长期预后较差。在此,我们研究了两名c.647T>G p.L216R等位基因纯合的HLCS缺乏症患者的细胞系。与正常成纤维细胞相比,患者的成纤维细胞生长受到损害。而且患者细胞对培养基中生物素的消耗不敏感,重新添加生物素也无法恢复其生长速率。通过对p.L216R蛋白的特性分析进一步研究了HLCS缺乏的分子基础。在多种羧化酶缺乏症(MCD)细胞系和正常细胞系中均检测到HLCS mRNA。然而,在患者细胞中未检测到蛋白和酶活性。体外动力学分析表明,重组表达的p.L216R酶活性严重受损,额外添加生物素也无法提高其活性。此外,突变蛋白的周转率是野生型HLCS的两倍。这些结果有助于为这种p.L216R形式的HLCS对生物素反应不完全提供分子解释。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验